{"id":"193c781d-00e2-4b1e-b724-f1454f305893","modelId":"894204d2-44c2-4f9e-9261-5d64481f866a","versionId":null,"locationId":"5f4611fa-0166-4c4f-bb83-13ee9b83d4ba","operatorId":"bc532371-0bd2-47c6-9edc-7f5f701b2a24","ownerId":null,"slug":"parker-indego-nashville-tennessee-usa","status":"operational","firstSeen":"2015-10-22T00:00:00.000Z","statusChangeReason":null,"contractType":null,"pilotOutcome":null,"endedAt":null,"unitsOnSite":null,"tasksPerformed":null,"shiftStructure":null,"hoursPerDay":null,"siteType":null,"operatorConfirmed":null,"humanSupervisionOnsite":null,"locationPrecisionTier":null,"deploymentScale":null,"siteEnvironment":null,"operatorType":null,"sourceQualityTier":null,"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://www.todaysmedicaldevelopments.com/news/medical-device-design-parker-hannifin-indego-exoskeleton-paralyzed-walking-102215/","label":"Parker to supply Indego Exoskeletons for DOD-funded study","title":"Parker to supply Indego Exoskeletons for DOD-funded study","mediaType":"article","sourceName":"Today's Medical Developments","publishedAt":"2015-10-22"}],"notes":"Vanderbilt Medical Center participated in 4-year DOD-funded multi-center study. 54 subjects enrolled across three studies including home/community use. Technology originally licensed from Vanderbilt University.","keyFacts":[],"reviewNote":null,"exposureHours":null,"deploymentMilesEstimate":null,"exposureBasis":null,"customerSegment":null,"scaleTier":null,"contractValueUsd":null,"contractValueBasis":null,"customerCompanyId":null,"customerExternalName":null,"createdAt":"2026-08-15T09:05:00.044Z","updatedAt":"2026-08-17T04:53:27.309Z","model":{"id":"894204d2-44c2-4f9e-9261-5d64481f866a","companyId":"bc532371-0bd2-47c6-9edc-7f5f701b2a24","modelName":"Indego","slug":"parker-indego","description":"Parker Hannifin's Indego is a powered lower-limb exoskeleton, FDA-cleared via 510(k) in 2016, intended to enable individuals with spinal cord injury at levels T7 to L5 to perform ambulatory functions with supervision of a specially trained companion.","formFactor":"exoskeleton","industryVertical":null,"environment":null,"maturityStage":"research","lifecycleState":"active","supersededByModelId":null,"specs":{"class":"powered lower-limb exoskeleton","clearance":"FDA 510(k) 2016","indication":"SCI T7-L5"},"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://www.southcarolinablues.com/web/public/brands/medicalpolicy/external-policies/powered-exoskeleton-for-ambulation-in-patients-with-lower-limb-disabilities/","sourceName":"Parker Hannifin / Indego"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"manufacturerTermForTeleop":null,"keyFacts":[{"label":"Form factor","value":"powered lower-limb exoskeleton"},{"label":"Clearance","value":"FDA 510(k) 2016"},{"label":"Indication","value":"SCI T7-L5"}],"createdAt":"2026-06-24T07:16:07.432Z","updatedAt":"2026-08-16T04:14:17.537Z","unitsInFieldClaimed":null,"unitsInFieldVerified":null,"unitsManufacturedClaimed":null,"unitsManufacturedVerified":null,"unitsAsOf":null,"unitsSource":null,"salesModel":null,"priceUndisclosedSince":null,"autonomyClass":null,"autonomyStatement":null,"autonomyStatementSource":null,"demoForensics":null,"exportControlClass":null,"minCommitment":null,"warrantyTerms":null,"serviceModel":null,"productionRateClaimed":null,"productionRateEvidenced":null,"teleopRatioDisclosed":null,"interventionRateDisclosed":null,"company":{"id":"bc532371-0bd2-47c6-9edc-7f5f701b2a24","name":"Parker Hannifin Indego","slug":"parker-hannifin-exoskeleton","description":"Parker Hannifin Indego was a division of Parker Hannifin that developed the Indego powered lower-limb exoskeleton for individuals with spinal cord injuries. Licensed from Vanderbilt University in 2012, the device received FDA clearance in March 2016 and CE Mark in November 2015, enabling users to stand and walk for up to four hours. Parker Hannifin sold the Indego business to Ekso Bionics in December 2022 for $10 million, exiting the exoskeleton market.","status":"active","founded":2012,"hq":"Cleveland, OH, USA","hqLat":41.4996574,"hqLng":-81.6936772,"hqGeocodedAt":"2026-08-05T14:43:06.985Z","hqAddress":null,"hqPrecision":null,"website":null,"fundingTotal":null,"type":"hardware","reviewStatus":"reviewed","lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://www.indego.com/","title":"Indego","date_accessed":"2026-06-07"}],"keyFacts":[{"label":"Robot","value":"Powered lower limb exoskeleton for rehabilitation and personal use"},{"label":"Products","value":"Indego Therapy and Indego Personal"},{"label":"Parent","value":"Parker Hannifin Corporation (NYSE: PH)"},{"label":"Product","value":"Indego — powered lower-limb exoskeleton"},{"label":"Use case","value":"Spinal cord injury rehabilitation, mobility assistance"},{"label":"CEO","value":"Tom Williams (Chairman & CEO of Parker Hannifin)"},{"label":"Business unit head","value":"Achilleas Dorotheou (VP, Human Motion and Control)"},{"label":"CTO","value":"Mark Czaja (Chief Technology and Innovation Officer)"},{"label":"Technology origin","value":"Licensed from Vanderbilt University (2012)"},{"label":"FDA clearance","value":"March 2016"},{"label":"CE Mark","value":"November 2015"},{"label":"Acquired by","value":"Ekso Bionics (December 2022, $10M)"},{"label":"DOD study funder","value":"CDMRP/SCIRP (4-year multi-center study)"},{"label":"Clinical trial","value":"Largest US exoskeleton clinical trial, 1,200+ sessions, no serious adverse events"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-06-08T04:05:18.726Z","updatedAt":"2026-08-15T09:01:49.045Z"}},"version":null,"location":{"id":"5f4611fa-0166-4c4f-bb83-13ee9b83d4ba","name":"Nashville, Tennessee, USA","slug":"nashville-tennessee-usa","kind":"city","parentLocationId":null,"region":null,"lat":null,"lng":null,"reviewStatus":"reviewed","aliases":[],"collisionRisk":"high","reviewNote":null,"createdAt":"2026-08-12T23:17:09.609Z","updatedAt":"2026-08-15T09:03:26.499Z"},"operator":{"id":"bc532371-0bd2-47c6-9edc-7f5f701b2a24","name":"Parker Hannifin Indego","slug":"parker-hannifin-exoskeleton","description":"Parker Hannifin Indego was a division of Parker Hannifin that developed the Indego powered lower-limb exoskeleton for individuals with spinal cord injuries. Licensed from Vanderbilt University in 2012, the device received FDA clearance in March 2016 and CE Mark in November 2015, enabling users to stand and walk for up to four hours. Parker Hannifin sold the Indego business to Ekso Bionics in December 2022 for $10 million, exiting the exoskeleton market.","status":"active","founded":2012,"hq":"Cleveland, OH, USA","hqLat":41.4996574,"hqLng":-81.6936772,"hqGeocodedAt":"2026-08-05T14:43:06.985Z","hqAddress":null,"hqPrecision":null,"website":null,"fundingTotal":null,"type":"hardware","reviewStatus":"reviewed","lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://www.indego.com/","title":"Indego","date_accessed":"2026-06-07"}],"keyFacts":[{"label":"Robot","value":"Powered lower limb exoskeleton for rehabilitation and personal use"},{"label":"Products","value":"Indego Therapy and Indego Personal"},{"label":"Parent","value":"Parker Hannifin Corporation (NYSE: PH)"},{"label":"Product","value":"Indego — powered lower-limb exoskeleton"},{"label":"Use case","value":"Spinal cord injury rehabilitation, mobility assistance"},{"label":"CEO","value":"Tom Williams (Chairman & CEO of Parker Hannifin)"},{"label":"Business unit head","value":"Achilleas Dorotheou (VP, Human Motion and Control)"},{"label":"CTO","value":"Mark Czaja (Chief Technology and Innovation Officer)"},{"label":"Technology origin","value":"Licensed from Vanderbilt University (2012)"},{"label":"FDA clearance","value":"March 2016"},{"label":"CE Mark","value":"November 2015"},{"label":"Acquired by","value":"Ekso Bionics (December 2022, $10M)"},{"label":"DOD study funder","value":"CDMRP/SCIRP (4-year multi-center study)"},{"label":"Clinical trial","value":"Largest US exoskeleton clinical trial, 1,200+ sessions, no serious adverse events"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-06-08T04:05:18.726Z","updatedAt":"2026-08-15T09:01:49.045Z"},"owner":null,"derived":{"trustTier":"unverified","currentPosture":null},"jsonLd":{"@context":"https://schema.org","@type":"Event","@id":"https://registry.deploy.report/deployments/parker-indego-nashville-tennessee-usa","url":"https://registry.deploy.report/deployments/parker-indego-nashville-tennessee-usa","name":"Indego at Nashville, Tennessee, USA","identifier":"193c781d-00e2-4b1e-b724-f1454f305893","startDate":"2015-10-22T00:00:00.000Z","location":{"@type":"Place","@id":"https://registry.deploy.report/locations/nashville-tennessee-usa","name":"Nashville, Tennessee, USA"},"organizer":{"@type":"Organization","@id":"https://registry.deploy.report/companies/parker-hannifin-exoskeleton","name":"Parker Hannifin Indego"},"about":{"@type":"Product","@id":"https://registry.deploy.report/models/parker-indego","name":"Indego"},"publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":"research","lifecycle_state":"active","architectural_position":{"cohort":"exoskeleton","sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":1,"primary_source_types":[]}}}